1. Current Share Price and Valuation
- ABLBio stock share price: around KRW 178,800 (as of market close on 2025-11-21, +0.85%)
- 52-week range: KRW 25,950 ~ 195,500
- 52-week low: KRW 25,950 on 2024-11-27
- 52-week high: KRW 195,500 on 2025-11-14
- Market capitalization: around KRW 9.8 trillion (around 4th place on KOSDAQ by market cap)
- 1-year return: over +500% (about +512% over one year)
- PER: Negative, so PER is shown as “–” (on some sites it appears as –100 to –300x)
- PBR: around 50x+ (most sites show roughly 50–55x)
In summary:
“It’s a company that hasn’t yet entered a full-fledged profit phase,
but is trading at around KRW 10 trillion market cap and PBR 50x as a ‘platform / deal-driven’ flagship biotech name.”
Analyst consensus (based on Investing.com data):
- 12-month average target price: around KRW 103,000
- Highest target: KRW 190,000, lowest: KRW 80,000, and all analyst ratings are ‘Buy’.
→ Compared to the current share price (KRW 170,000–180,000), the average target price is actually lower, so based on existing reports, you can say “the share price has run ahead of the targets relative to fundamentals and deals.”
However, in more recent reports, after the Lilly deal, some analysts have raised their targets to the KRW 180,000–190,000 range, describing ABL Bio as a company that could be “heading toward a KRW 10 trillion market cap.”
2. Recent Results and Financial Condition
① Q3 2025 Results (Single Quarter)
- Q3 2025 revenue: around KRW 1.4 billion (down –82.3% from KRW 7.9 billion a year earlier)
- Operating loss: around KRW 22.4 billion, with the loss widening by +52.4%
In other words, if you look only at Q3 as a standalone quarter, it’s “sharp revenue decline + expanding losses.”
(There was a one-time lump-sum recognition of license income in Q3 last year, so purely on a quarterly comparison the numbers look worse this year due to that base effect.)
② Q3 2025 Year-to-Date (Cumulative)
- Cumulative Q3 revenue: around KRW 79.3 billion (up from KRW 24.3 billion a year earlier → +226%)
- Operating loss: –KRW 10.7 billion (significantly reduced from –KRW 40.3 billion a year earlier)
- Net loss: –KRW 9.7 billion (improved from –KRW 36.5 billion a year earlier)
On top of this, there are:
- The GSK platform deal (April 2025, total up to ~KRW 4.1 trillion)
- The Lilly platform deal (November 2025, total up to ~KRW 3.8 trillion, upfront payment KRW 58.5 billion)
Since the upfront and milestone payments from these two mega deals are scheduled to be recognized over this year and next year, securities firms are projecting 2025 full-year revenue of KRW 100–140 billion and the possibility of turning profitable.
③ Financial Soundness
- Based on a 2024 corrected disclosure, shareholders’ equity stands at KRW 180.8 billion, so
the previous concern about capital impairment has been cleared. - As of the end of Q3 2025, ABL Bio held KRW 124.4 billion in cash and cash equivalents, and
with the GSK and Lilly upfront and milestone payments plus Lilly’s KRW 22 billion equity investment (via a paid-in capital increase),
news reports say the company is in the process of securing over KRW 200 billion in cash.
→ So, the level of financial risk that would put the company
“on the brink of delisting/watchlist because it’s about to run out of cash”
can be considered greatly alleviated at this point.
(Of course, as a company that spends very aggressively on R&D, it still needs close monitoring.)
3. Business Structure & Growth Story
1) Platform Business – Grabody-B / Grabody-T / ADC
ABL Bio is a bispecific antibody platform company, and its core asset is the BBB (blood–brain barrier) shuttle platform ‘Grabody-B’.
Major large-scale deals with big pharma over the last three years include:
- Sanofi – Bispecific antibodies for degenerative brain diseases such as Parkinson’s (ABL301 / SAR446159 etc.), total size of about KRW 1.2 trillion
- GSK – Grabody-B platform deal, total up to about KRW 4.1 trillion (including KRW 74 billion upfront)
- Eli Lilly – Grabody-B platform deal, total up to about KRW 3.8 trillion, with USD 40 million (about KRW 58.5 billion) in upfront payment Plus, an additional KRW 22 billion in strategic equity investment from Lilly
(175,079 shares acquired at KRW 125,900 per share) - In the past, ABL Bio also signed licensing deals worth several hundred billion KRW with Compass Therapeutics and SystImmune (and related partners).
The combined total value of these technology out-licensing deals is assessed at around KRW 10 trillion,
so the market broadly views ABL Bio as a “leading BBB shuttle platform company in Korea.”
2) Key Pipelines
- ABL301 (SAR446159) – Synucleinopathies such as Parkinson’s disease
- A bispecific antibody candidate for Parkinson’s disease using the Grabody-B platform.
- In U.S. Phase 1 trials (in healthy subjects), safety and tolerability have been confirmed, and the company is now preparing a subsequent Phase 2 trial.
- ABL001 (Biliary tract cancer treatment)
- Partner company Compass Therapeutics is conducting Phase 2/3 trials in the U.S.
- The company considers key data in April 2026 → regulatory approval and royalty revenue in 2027 as an important milestone.
- ABL111 (First-line gastric cancer candidate, based on Grabody-T)
- Being developed as a first-line treatment for HER2-negative gastric cancer, and
- The company is preparing a Phase 1b expansion trial.
- ADC pipeline (ABL206, ABL209)
- Through its U.S. subsidiary Neukio Bio (or NeoC Bio; context: U.S. subsidiary), ABL Bio is developing bispecific antibody-based ADCs.
- It plans to sequentially submit FDA Phase 1 IND applications for these programs in Q4 2025 ~ Q1 2026.
The company and analysts describe “around 2027 – when ABL001 wins approval and the cumulative effect of platform deals kicks in” as a key inflection point.
4. Outlook – Positive Points
① Validation of the BBB Shuttle Platform ‘Grabody-B’
The fact that three top-tier global pharma companies—Sanofi, GSK, and Lilly—have all put money into the same platform (Grabody-B)
essentially means that the technology’s reliability has been externally validated to a certain degree.
In particular, the Lilly deal was signed without a prior MTA (material transfer agreement) and involved purchasing the platform itself upfront,
so many view this as a sign that trust at the platform level is quite high.
② Potential for Additional Deals
At global conferences such as J.P. Morgan Healthcare and BIO USA, the company has said things like:
- “We see further out-licensing opportunities in additional targets such as tau and amyloid,”
- “It’s reasonable to expect that another deal could very well happen.”
Media reports and analyst notes also see “confirmation of muscle delivery in joint research with Ionis” as a potential upside trigger,
as it would support expanding indications beyond CNS.
③ Improved Financial Strength and Cash Buffer
Thanks to increased cumulative revenue in 2025 and the two mega-deals,
- the market is talking about the possibility of annual revenue of KRW 100–140 billion and a swing to profit, and
- once you include cash and cash equivalents plus equity financing and upfronts,
the company has said that it will be able to
“run R&D without worrying about funding for at least the next two years.”
→ In other words, the core premium story being priced in now is:
“An R&D-focused biotech with relatively low near-term cash risk,
backed by a platform that has already been signed onto three times by global big pharma.”
5. Risks and Points to Watch
Here’s the crucial part.
At the current share price level, the biggest risks are “valuation and volatility.”
① Extremely High Valuation
- With PBR 50x+ and market cap of KRW 9–10 trillion,
and 2025 expected revenue of only KRW 100–140 billion, the implied PSR (price-to-sales ratio) is around 60–90x on a simple revenue basis. - PER is still negative, so it’s hard to discuss whether the stock is cheap or expensive based on earnings.
More precisely, you can say that the stock price heavily reflects
a large premium purely based on “platform value” and expectations about future deals/approvals.
② “Lumpy” Recognition Structure of Results
- In typical out-licensing biotech deals, revenue comes from:
- Upfront payments
- Development / approval / sales-based milestones
- Royalties after commercialization
- In Q3 2025, single-quarter revenue was only KRW 1.4 billion and operating losses widened,
and even the cumulative improvement is largely dependent on when deals are recognized.
→ If there is a “deal gap” period, investors may start saying
“Revenues and profits aren’t coming through as much as expected,” and
this can trigger valuation compression (multiple contraction) and large swings in the share price.
③ Clinical and Regulatory Risks in the Pipeline
- ABL001, ABL301, ABL111, and the ADC pipeline are all still before full regulatory approval.
- At each stage—ABL001 Phase 2/3, ABL301 Phase 2, ABL111 Phase 1b, ABL206/209 Phase 1—
if any efficacy or safety issues arise,
the share price is likely to take a significant hit.
④ Volatility and Order-Flow Risk
- With a 1-year return of over +500% and a 52-week range from KRW 25,950 up to KRW 195,500,
the stock has shown a clear “rollercoaster” price pattern. - Because it is heavily affected by institutional/foreign flows, short-selling, and events
(deal announcements, conference presentations, etc.),
it is a high-volatility stock that can move 10–20% in a single day.
6. Summary from an Individual Investor’s Perspective
One-line characterization:
“The leading domestic name in bispecific antibody / BBB shuttle platforms,
a company that has successfully out-licensed around KRW 10 trillion in cumulative deals with three big pharma companies,
but one that trades at around KRW 10 trillion market cap and PBR 50x,
making it an extremely high-premium biotech stock.”
Short-Term View (Within 1 Year)
- Since this is right after the Lilly deal, this could be the “deal announcement → peak in expectations” phase.
- Over the next year, the share price could move sharply around news on:
- The actual timing of Lilly’s upfront payment
- IND submissions for ABL206/209, data updates for ABL001
- Additional platform deals or major conference presentations
- Overall conditions in global equity and biotech markets
→ It is best viewed as being in a “news-driven trading + high-volatility market” environment,
and because the stock has already risen so much, there is always a risk of sharp pullbacks after short-term spikes.
Medium- to Long-Term View (3–5 Years)
Bull (Best-Case) Scenario
- ABL001 wins U.S. approval around 2027 and royalty flows begin in earnest
- ABL301 and the ADC pipeline deliver meaningful efficacy/safety data
- 1–2 additional big pharma deals are signed using Grabody-B
→ If a structure combining “platform + tangible drug sales/royalties” is realized,
the currently high valuation could be partially justified,
and there could still be room to maintain high multiples or see further upside over the long term.
Base/Neutral Scenario
- Deals continue to come through intermittently,
but clinical progress is slower than expected, and
revenue/profit only spike in the years when new deals are signed.
→ The stock trades in a high-valuation range around KRW 10 trillion market cap, essentially in a wide box.
Bear (Downside) Scenario
- For key pipelines (ABL001, ABL301, ADC, etc.),
there are efficacy or safety issues, or significant delays in approval - There are no additional big deals, and existing partners slow down development
→ If the perception spreads that
“The platform is fine, but in the end, no real, commercialized drugs came out of it,”
there is ample possibility of valuation compression (multiple contraction) and a large correction in the share price.
7. Practical Use Case (General View)
From an individual investor’s point of view, ABL Bio is:
- Not a “long-term dividend / cash-cow” type name,
- but rather a stock that should be placed in the high-risk, high-return growth segment of a portfolio.
Given that:
- The stock has already risen several hundred percent in a year, and
- The valuation is extremely high,
it is burdensome to approach this name without:
- Limiting it to only a small portion of the portfolio, and
- Setting clear stop-loss and take-profit rules in advance (e.g., –15% stop-loss / +30% partial profit-taking).